Birdwatch Note
2023-03-24 20:02:34 UTC - NOT_MISLEADING
Not not needed. Tweet and doctor are correct. WHO recommended against prescribing Remdesivir (VEKLURY®) on Nov. 20, 2020. https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients The FDA approved Remdesivir on Jan 31, 2022. CMS added Remdesivir (VEKLURY®) to the list of treatments eligible for bonus. https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap
Written by C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1639319822667218944
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1639357057118683136
- noteId - 1639357057118683136
- participantId -
- noteAuthorParticipantId - C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3 Participant Details
- createdAtMillis - 1679688154856
- tweetId - 1639319822667218944
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 1
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Not not needed. Tweet and doctor are correct. WHO recommended against prescribing Remdesivir (VEKLURY®) on Nov. 20, 2020. https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients The FDA approved Remdesivir on Jan 31, 2022. CMS added Remdesivir (VEKLURY®) to the list of treatments eligible for bonus. https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-03-24 20:02:34 UTC (1679688154856) |
1969-12-31 23:59:59 UTC (-1) |
2023-03-26 02:09:44 UTC (1679796584421) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-03-24 19:26:50 -0500 | Rating Details | |
2023-03-24 19:21:03 -0500 | Rating Details | |
2023-03-24 19:03:16 -0500 | Rating Details | |
2023-03-24 19:00:55 -0500 | Rating Details | |
2023-03-24 18:55:43 -0500 | Rating Details | |
2023-03-24 18:54:42 -0500 | Rating Details | |
2023-03-24 18:51:06 -0500 | Rating Details | |
2023-03-24 18:48:35 -0500 | Rating Details | |
2023-03-24 18:32:55 -0500 | Rating Details | |
2023-03-24 18:27:05 -0500 | Rating Details | |
2023-03-24 18:25:19 -0500 | Rating Details | |
2023-03-24 18:23:08 -0500 | Rating Details | |
2023-03-24 18:22:31 -0500 | Rating Details | |
2023-03-24 18:21:23 -0500 | Rating Details | |
2023-03-24 18:21:19 -0500 | Rating Details | |
2023-03-24 18:14:59 -0500 | Rating Details | |
2023-03-24 18:11:49 -0500 | Rating Details | |
2023-03-24 18:11:18 -0500 | Rating Details | |
2023-03-24 18:06:31 -0500 | Rating Details | |
2023-03-24 18:05:32 -0500 | Rating Details | |
2023-03-24 18:03:46 -0500 | Rating Details | |
2023-03-24 18:03:33 -0500 | Rating Details | |
2023-03-24 18:00:16 -0500 | Rating Details | |
2023-03-24 17:57:12 -0500 | Rating Details | |
2023-03-24 17:57:09 -0500 | Rating Details | |
2023-03-24 17:55:35 -0500 | Rating Details | |
2023-03-24 17:51:52 -0500 | Rating Details | |
2023-03-24 17:49:33 -0500 | Rating Details | |
2023-03-24 17:39:19 -0500 | Rating Details | |
2023-03-24 17:38:30 -0500 | Rating Details | |
2023-03-24 17:38:15 -0500 | Rating Details | |
2023-03-24 17:32:32 -0500 | Rating Details | |
2023-03-24 17:32:26 -0500 | Rating Details | |
2023-03-24 17:32:18 -0500 | Rating Details | |
2023-03-24 17:27:42 -0500 | Rating Details | |
2023-03-24 17:25:25 -0500 | Rating Details | |
2023-03-24 17:24:45 -0500 | Rating Details | |
2023-03-24 17:12:51 -0500 | Rating Details | |
2023-03-24 17:02:30 -0500 | Rating Details | |
2023-03-24 17:00:04 -0500 | Rating Details | |
2023-03-24 16:55:57 -0500 | Rating Details | |
2023-03-24 16:50:56 -0500 | Rating Details | |
2023-03-24 16:48:33 -0500 | Rating Details | |
2023-03-24 16:47:05 -0500 | Rating Details | |
2023-03-24 16:31:32 -0500 | Rating Details | |
2023-03-24 16:29:34 -0500 | Rating Details | |
2023-03-24 16:18:54 -0500 | Rating Details | |
2023-03-24 16:16:20 -0500 | Rating Details | |
2023-03-24 16:10:05 -0500 | Rating Details | |
2023-03-24 15:45:56 -0500 | Rating Details | |
2023-03-24 15:16:52 -0500 | Rating Details | |
2023-03-24 15:04:31 -0500 | Rating Details | |
2023-03-25 10:11:30 -0500 | Rating Details | |
2023-03-25 09:32:56 -0500 | Rating Details | |
2023-03-25 08:38:01 -0500 | Rating Details | |
2023-03-25 08:22:36 -0500 | Rating Details | |
2023-03-25 06:24:46 -0500 | Rating Details | |
2023-03-25 05:53:28 -0500 | Rating Details | |
2023-03-25 05:23:18 -0500 | Rating Details | |
2023-03-25 03:50:15 -0500 | Rating Details | |
2023-03-24 22:41:56 -0500 | Rating Details | |
2023-03-24 22:02:38 -0500 | Rating Details | |
2023-03-24 20:46:26 -0500 | Rating Details | |
2023-03-24 20:09:37 -0500 | Rating Details | |
2023-03-24 19:48:58 -0500 | Rating Details | |
2023-03-24 19:41:20 -0500 | Rating Details | |
2023-03-26 04:34:00 -0500 | Rating Details | |
2023-03-25 22:13:51 -0500 | Rating Details | |
2023-03-25 21:49:45 -0500 | Rating Details | |
2023-03-25 21:28:56 -0500 | Rating Details | |
2023-03-25 21:21:44 -0500 | Rating Details | |
2023-03-25 16:39:17 -0500 | Rating Details | |
2023-03-25 12:39:16 -0500 | Rating Details | |
2023-03-25 10:26:42 -0500 | Rating Details | |
2023-04-01 11:08:28 -0500 | Rating Details | |
2023-03-24 16:24:48 -0500 | Rating Details | |
2023-03-25 05:53:28 -0500 | Rating Details | |
2023-03-24 18:51:06 -0500 | Rating Details | |
2023-03-25 16:39:17 -0500 | Rating Details | |
2023-03-24 17:49:33 -0500 | Rating Details | |
2023-03-24 16:10:05 -0500 | Rating Details | |
2023-03-25 09:32:56 -0500 | Rating Details | |
2023-03-24 17:00:04 -0500 | Rating Details | |
2023-03-24 18:06:31 -0500 | Rating Details | |
2023-03-24 18:22:31 -0500 | Rating Details | |
2023-03-24 16:24:48 -0500 | Rating Details | |
2023-03-24 18:00:16 -0500 | Rating Details | |
2023-03-24 16:29:34 -0500 | Rating Details | |
2023-03-26 04:34:00 -0500 | Rating Details | |
2023-03-24 18:14:59 -0500 | Rating Details | |
2023-03-25 08:22:36 -0500 | Rating Details | |
2023-03-24 18:32:55 -0500 | Rating Details | |
2023-03-24 22:02:38 -0500 | Rating Details | |
2023-03-25 10:26:42 -0500 | Rating Details | |
2023-03-24 22:41:56 -0500 | Rating Details | |
2023-03-25 03:50:15 -0500 | Rating Details | |
2023-03-24 18:03:33 -0500 | Rating Details | |
2023-03-24 15:04:31 -0500 | Rating Details | |
2023-03-24 17:27:42 -0500 | Rating Details | |
2023-03-24 15:16:52 -0500 | Rating Details | |
2023-03-24 17:24:45 -0500 | Rating Details | |
2023-03-24 17:57:09 -0500 | Rating Details | |
2023-03-24 17:57:12 -0500 | Rating Details | |
2023-03-24 16:47:05 -0500 | Rating Details | |
2023-03-24 17:38:30 -0500 | Rating Details | |
2023-03-25 10:11:30 -0500 | Rating Details | |
2023-03-24 19:48:58 -0500 | Rating Details | |
2023-03-24 19:41:20 -0500 | Rating Details | |
2023-03-25 12:39:16 -0500 | Rating Details | |
2023-03-24 17:32:32 -0500 | Rating Details | |
2023-03-25 21:21:44 -0500 | Rating Details | |
2023-04-01 11:08:28 -0500 | Rating Details | |
2023-03-24 18:11:18 -0500 | Rating Details | |
2023-03-24 19:03:16 -0500 | Rating Details | |
2023-03-25 05:23:18 -0500 | Rating Details | |
2023-03-24 18:27:05 -0500 | Rating Details | |
2023-03-24 20:46:26 -0500 | Rating Details | |
2023-03-24 18:23:08 -0500 | Rating Details | |
2023-03-24 18:55:43 -0500 | Rating Details | |
2023-03-24 16:55:57 -0500 | Rating Details | |
2023-03-24 18:21:19 -0500 | Rating Details | |
2023-03-24 16:18:54 -0500 | Rating Details | |
2023-03-24 18:48:35 -0500 | Rating Details | |
2023-03-24 19:21:03 -0500 | Rating Details | |
2023-03-24 18:21:23 -0500 | Rating Details | |
2023-03-25 22:13:51 -0500 | Rating Details | |
2023-03-24 17:02:30 -0500 | Rating Details | |
2023-03-24 18:05:32 -0500 | Rating Details | |
2023-03-24 17:38:15 -0500 | Rating Details | |
2023-03-24 16:50:56 -0500 | Rating Details | |
2023-03-25 08:38:01 -0500 | Rating Details | |
2023-03-24 18:54:42 -0500 | Rating Details | |
2023-03-24 17:12:51 -0500 | Rating Details | |
2023-03-24 18:25:19 -0500 | Rating Details | |
2023-03-24 15:45:56 -0500 | Rating Details | |
2023-03-25 06:24:46 -0500 | Rating Details | |
2023-03-24 17:25:25 -0500 | Rating Details | |
2023-03-24 17:32:18 -0500 | Rating Details | |
2023-03-24 16:48:33 -0500 | Rating Details | |
2023-03-24 17:55:35 -0500 | Rating Details | |
2023-03-24 17:51:52 -0500 | Rating Details | |
2023-03-24 16:16:20 -0500 | Rating Details | |
2023-03-24 17:39:19 -0500 | Rating Details | |
2023-03-24 18:03:46 -0500 | Rating Details | |
2023-03-24 19:00:55 -0500 | Rating Details | |
2023-03-24 17:32:26 -0500 | Rating Details | |
2023-03-24 16:31:32 -0500 | Rating Details | |
2023-03-24 19:26:50 -0500 | Rating Details | |
2023-03-24 18:11:49 -0500 | Rating Details | |
2023-03-25 21:28:56 -0500 | Rating Details | |
2023-03-24 20:09:37 -0500 | Rating Details | |
2023-03-25 21:49:45 -0500 | Rating Details |